Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: Risk for serum sickness
Naunyn-Schmiedeberg's archives of pharmacology
Open Access Publication
Rights and Permissions
Molderings, G.J., Dumoulin, F.L., Homann, J. et al. Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: risk for serum sickness. Naunyn-Schmiedeberg's Arch Pharmacol 393, 1573–1580 (2020). https://doi.org/10.1007/s00210-020-01886-2 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Molderings, G J; Weinstock, L B; and et al., "Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: Risk for serum sickness." Naunyn-Schmiedeberg's archives of pharmacology. 393, 9. 1573 - 1580. (2020).
Supplemental material is available for this article at publisher site.